Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
Habimana DS, Ngabonziza JCS, Migambi P, Mucyo-Habimana Y, Mutembayire G, Byukusenge F, Habiyambere I, Remera E, Mugwaneza P, Mwikarago IE, Mazarati JB, Turate I, Nsanzimana S, Decroo T, de Jong CB. Habimana DS, et al. Among authors: migambi p. Am J Trop Med Hyg. 2021 May 17;105(1):47-53. doi: 10.4269/ajtmh.20-1361. Am J Trop Med Hyg. 2021. PMID: 33999845 Free PMC article.
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
Ngabonziza JS, Habimana YM, Decroo T, Migambi P, Dushime A, Mazarati JB, Rigouts L, Affolabi D, Ivan E, Meehan CJ, Van Deun A, Fissette K, Habiyambere I, Nyaruhirira AU, Turate I, Semahore JM, Ndjeka N, Muvunyi CM, Condo JU, Gasana M, Hasker E, Torrea G, de Jong BC. Ngabonziza JS, et al. Among authors: migambi p. Int J Tuberc Lung Dis. 2020 Mar 1;24(3):329-339. doi: 10.5588/ijtld.19.0298. Int J Tuberc Lung Dis. 2020. PMID: 32228764
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Ngabonziza JCS, Van Deun A, Migambi P, Niyigena EB, Dusabe T, Habimana YM, Ushizimpumu B, Mulders W, Decroo T, Affolabi D, Supply P, de Jong BC, Rigouts L. Ngabonziza JCS, et al. Among authors: migambi p. Am J Trop Med Hyg. 2020 Oct;103(4):1443-1446. doi: 10.4269/ajtmh.20-0201. Am J Trop Med Hyg. 2020. PMID: 32618257 Free PMC article.
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.
Ngabonziza JCS, Rigouts L, Torrea G, Decroo T, Kamanzi E, Lempens P, Rucogoza A, Habimana YM, Laenen L, Niyigena BE, Uwizeye C, Ushizimpumu B, Mulders W, Ivan E, Tzfadia O, Muvunyi CM, Migambi P, Andre E, Mazarati JB, Affolabi D, Umubyeyi AN, Nsanzimana S, Portaels F, Gasana M, de Jong BC, Meehan CJ. Ngabonziza JCS, et al. Among authors: migambi p. J Clin Tuberc Other Mycobact Dis. 2022 Jan 24;27:100299. doi: 10.1016/j.jctube.2022.100299. eCollection 2022 May. J Clin Tuberc Other Mycobact Dis. 2022. PMID: 35146133 Free PMC article. Review.
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda.
Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, Torrea G, Massou F, de Rijk WB, Ushizimpumu B, Niyigena EB, Ivan E, Semahore JM, Mazarati JB, Merle CS, Supply P, Affolabi D, Rigouts L, de Jong BC. Ngabonziza JCS, et al. Among authors: migambi p. Lancet Microbe. 2020 Jun;1(2):e74-e83. doi: 10.1016/S2666-5247(20)30007-0. Epub 2020 Jun 8. Lancet Microbe. 2020. PMID: 35544156 Free article.
Management of falsepositive rifampicin resistant Xpert MTB/RIF - Authors' reply.
Ngabonziza JCS, Decroo T, Torrea G, Migambi P, Van Deun A, Rigouts L, de Jong BC. Ngabonziza JCS, et al. Among authors: migambi p. Lancet Microbe. 2020 Oct;1(6):e239. doi: 10.1016/S2666-5247(20)30125-7. Epub 2020 Oct 7. Lancet Microbe. 2020. PMID: 35544219 Free article. No abstract available.
11 results